Search

Your search keyword '"Pronk N"' showing total 188 results
Start Over Author "Pronk N"
188 results on '"Pronk N"'

1. Imatinib in patients with severe COVID-19: a randomised, doubleblind, placebo-controlled, clinical trial (vol 9, pg 957, 2021)

Author

Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J.R., Smeele, P.J., Azhang, S., Bartelink, I.H., Bayoumy, A.A., Bet, P.M., Boersma, W., Bonta, P.I., Boomars, K.A.T., Bos, L.D.J., Bragt, J.J.M.H. van, Braunstahl, G.J., Celant, L.R., Eger, K.A.B., Geelhoed, J.J.M., Glabbeek, Y.L.E. van, Grotjohan, H.P., Hagens, L.A., Happe, C.M., Hazes, B.D., Heunks, L.M.A., Heuvel, M. van den, Hoefsloot, W., Hoek, R.J.A., Hoekstra, R., Hofstee, H.M.A., Juffermans, N.P., Kemper, E.M., Kos, R., Kunst, P.W.A., Lammers, A., Lee, I. van der, Lee, E.L. van der, Maitland-van der Zee, A.H., Asam, P.F.M.M., Mieras, A., Muller, M., Neefjes, E.C.W., Nossent, E.J., Oswald, L.M.A., Overbeek, M.J., Pamplona, C.C., Paternotte, N., Pronk, N., Raaf, M.A. de, Raaij, B.F.M. van, Reijrink, M., Schultz, M.J., Neto, A.S., Slob, E.M.A., Smeenk, F.W.J.M., Smit, M.R., Smits, A.J., Stalenhoef, J.E., Tuinman, P.R., Vanhov, A.L.E.M., Wessels, J.N., Wezenbeek, J.C.C. van, Noordegraaf, A.V., Ma, F.S. de, and Bogaard, H.J.

Published
2021

2. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Author

Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J.R., Smeele, P.J., Azhang, S., Bartelink, I.H., Bayoumy, A.A., Bet, P.M., Boersma, W., Bonta, P.I., Boomars, K.A., Bos, L.D., Bragt, J. van, Braunstahl, G.J., Celant, L.R., Eger, K.A.B., Geelhoed, J.J.M., Glabbeek, Y.L.E. van, Grotjohan, H.P., Hagens, L.A., Happe, C.M., Hazes, B.D., Heunks, L.M., Heuvel, M.M. van den, Hoefsloot, W., Hoek, R.J.A., Hoekstra, R., Hofstee, H.M.A., Juffermans, N.P., Kemper, E.M., Kos, R., Kunst, P.W., Lammers, A., Lee, I. van der, Lee, E.L. van der, Maitland-van der Zee, A.H., Asam, P.F.M. Mau, Mieras, A., Muller, Mirte, Neefjes, E.C.W., Nossent, E.J., Oswald, L.M.A., Overbeek, M.J., Pamplona, C.C., Paternotte, N., Pronk, N., Raaf, M.A. de, Raaij, B.F.M. van, Reijrink, M., Schultz, M.J., Neto, A. Serpa, Slob, E.M.A., Smeenk, F., Smit, M.R., Smits, A.J., Stalenhoef, J.E., Tuinman, P.R., Vanhove, A., Wessels, J.N., Wezenbeek, J.C.C. van, Noordegraaf, A. Vonk, Man, F.S. de, Bogaard, H.J., Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J.R., Smeele, P.J., Azhang, S., Bartelink, I.H., Bayoumy, A.A., Bet, P.M., Boersma, W., Bonta, P.I., Boomars, K.A., Bos, L.D., Bragt, J. van, Braunstahl, G.J., Celant, L.R., Eger, K.A.B., Geelhoed, J.J.M., Glabbeek, Y.L.E. van, Grotjohan, H.P., Hagens, L.A., Happe, C.M., Hazes, B.D., Heunks, L.M., Heuvel, M.M. van den, Hoefsloot, W., Hoek, R.J.A., Hoekstra, R., Hofstee, H.M.A., Juffermans, N.P., Kemper, E.M., Kos, R., Kunst, P.W., Lammers, A., Lee, I. van der, Lee, E.L. van der, Maitland-van der Zee, A.H., Asam, P.F.M. Mau, Mieras, A., Muller, Mirte, Neefjes, E.C.W., Nossent, E.J., Oswald, L.M.A., Overbeek, M.J., Pamplona, C.C., Paternotte, N., Pronk, N., Raaf, M.A. de, Raaij, B.F.M. van, Reijrink, M., Schultz, M.J., Neto, A. Serpa, Slob, E.M.A., Smeenk, F., Smit, M.R., Smits, A.J., Stalenhoef, J.E., Tuinman, P.R., Vanhove, A., Wessels, J.N., Wezenbeek, J.C.C. van, Noordegraaf, A. Vonk, Man, F.S. de, and Bogaard, H.J.

Abstract

Item does not contain fulltext, BACKGROUND: The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak. METHODS: This randomised, double-blind, placebo-controlled, clinical trial was done at 13 academic and non-academic teaching hospitals in the Netherlands. Hospitalised patients (aged ≥18 years) with COVID-19, as confirmed by an RT-PCR test for SARS-CoV-2, requiring supplemental oxygen to maintain a peripheral oxygen saturation of greater than 94% were eligible. Patients were excluded if they had severe pre-existing pulmonary disease, had pre-existing heart failure, had undergone active treatment of a haematological or non-haematological malignancy in the previous 12 months, had cytopenia, or were receiving concomitant treatment with medication known to strongly interact with imatinib. Patients were randomly assigned (1:1) to receive either oral imatinib, given as a loading dose of 800 mg on day 0 followed by 400 mg daily on days 1-9, or placebo. Randomisation was done with a computer-based clinical data management platform with variable block sizes (containing two, four, or six patients), stratified by study site. The primary outcome was time to discontinuation of mechanical ventilation and supplemental oxygen for more than 48 consecutive hours, while being alive during a 28-day period. Secondary outcomes included safety, mortality at 28 days, and the need for invasive mechanical ventilation. All efficacy and safety analyses were done in all randomised patients who had received at least one dose of study medication (modified intention-to-treat population). This study is registered with the EU Clinical Trials Register (EudraCT 2020-001236-10). FINDINGS: Between March 31, 2020, and Jan 4, 2021, 805 patients were screened, of whom 400 were eligible and randomly assigned to the imatinib group (n=204) or the placebo group (n=196)

Published
2021

37. Development of assessment tools to measure organizational support for employee health.

Author

Golaszewski T, Barr D, and Pronk N

Abstract

OBJECTIVE: To develop systems that measure and effect organizational support for employee health. METHODS: Multiple studies and developmental projects were reviewed that show the process of instrument development, metric quality testing, utilization within intervention studies, and prediction modeling efforts. RESULTS: Demographic patterns indicate high support levels and relationships of subsections to various employee health risks. Successes with the initial version have given rise to 2 additional evaluation tools. CONCLUSIONS: The availability of these systems illustrates how ecological models can be practically applied. Such efforts contribute to the paradigm shift in worksite health promotion that focuses on the organization as the target of intervention. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

39. Relationship between modifiable health risks and short-term health care charges.

Author

Pronk, Nicholas P., Goodman, Michael J., Martinson, Brian C., O'Connor, Patrick J., Pronk, N P, Goodman, M J, O'Connor, P J, and Martinson, B C

Subjects
MEDICAL economics, MEDICAL care costs, MEDICAL fees, PROFESSIONAL fees
Abstract

Context: If physical inactivity, obesity, and smoking status prove to contribute significantly to increased health care charges within a short period of time, health plans and payers may wish to invest in strategies to modify these risk factors. However, few data are available to guide such resource allocation decisions.Objective: To examine the relationship of modifiable health risks to subsequent health care charges after controlling for age, race, sex, and chronic conditions.Design, Setting, and Participants: Cohort study of a stratified random sample of 5689 adults (75.5% of total sample of 7535) aged 40 years or older who were enrolled in a Minnesota health plan and completed a 60-item questionnaire.Main Outcome Measure: Resource use as measured by billed health care charges from July 1, 1995, to December 31, 1996, compared by health risk (physical activity, body mass index [BMI], and smoking status).Results: The mean annual per patient charge in the total study population was $3570 (median, $600), and 15% of patients had no charges during the study period. After adjustment-for age, race, sex, and chronic disease status, physical activity (4.7% lower health care charges per active day per week), BMI (1.9% higher charges per BMI unit), current smoking status (18% higher charges), and history of tobacco use (25.8% higher charges) were prospectively related to health care charges over 18 months. Never-smokers with a BMI of 25 kg/m2 and who participated in physical activity 3 days per week had mean annual health care charges that were approximately 49% lower than physically inactive smokers with a BMI of 27.5 kg/m2.Conclusions: Our data suggest that adverse health risks translate into significantly higher health care charges within 18 months. Health plans or payers seeking to minimize health care charges may wish to consider strategic investments in interventions that effectively modify adverse health risks. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results